Panelists discuss how anticipated updates to cholesterol guidelines and related cardiovascular-kidney-metabolic health (CKM) guidelines this year are expected to shape low-density lipoprotein cholesterol (LDL-C) management strategies and influence treatment recommendations for high-risk patients.
As policy developments unfold rapidly at both the state and federal levels, Tom Kraus highlights the expanding scope of pharmacist practice through a wave of state-level legislation as a key opportunity.
Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.
Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an emphasis on personalizing therapy based on real-world data and patient-specific factors.
A panelist discusses how emerging research in non–small cell lung cancer (NSCLC) is focused on determining the most effective neoadjuvant/adjuvant approaches combining chemotherapy with immunotherapy, addressing tumor heterogeneity through potential combinations of targeted therapies, and investigating mechanisms of immunotherapy nonresponse to improve patient outcomes.
Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.
Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications.
Panelists discuss how key clinical and economic factors, such as efficacy, safety, cost-effectiveness, patient adherence, and proper monitoring, should be considered when evaluating new low-density lipoprotein cholesterol (LDL-C)–lowering medications for formulary inclusion, and how health care teams can optimize therapy management through patient counseling, monitoring, and coordination of injection therapies to improve outcomes.
Panelists discuss how ongoing monitoring and individualized treatment adjustments can help mitigate adverse events associated with low-density lipoprotein cholesterol (LDL-C)–lowering therapies while maintaining efficacy and explore strategies to navigate insurance barriers and ensure timely access to nonstatin LDL-C–lowering medications.
Laura Momoko Asakura, PharmD, BCOP, BCSPS, discusses the equitable use of oncology treatment pathway tools, highlighting that their utilization remains consistent across patient groups regardless of race, ethnicity, or insurance status.
Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible patients with newly diagnosed multiple myeloma from the CEPHEUS trial.
National Community Pharmacists Association President Jeff Harrell, PharmD, shares insights from this year’s event, highlighting its growing impact, the importance of engaging with policymakers, and the urgent issues facing independent pharmacies.
Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug interactions.
Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns.
Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings.
Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy.
A study of early-onset colorectal cancer found significant racial disparities, with younger patients more frequently diagnosed at advanced stages.
Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.
A panelist discusses how maintaining efficacy while preserving quality of life requires personalized approaches including dose adjustments or agent rotation based on specific toxicities, and how selecting the appropriate EGFR inhibitor depends on patient comorbidities, performance status, baseline conditions (such as interstitial lung disease or cardiac issues), and patient preferences.
Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.
Panelists discuss how recent FDA approvals and evolving evidence for second-line treatments, including ruxolitinib, ibrutinib, and belumosudil, are reshaping chronic graft-vs-host disease (cGVHD) management by offering tailored, evidence-based options for steroid-refractory patients.
A panelist discusses how the PALOMA-3 study demonstrated that subcutaneous amivantamab is noninferior to intravenous (IV) administration with significantly lower infusion-related reaction (IRR) rates (13% vs 66%), shorter administration time (5 minutes vs 5 hours), higher patient-reported convenience (85% vs 35%), and improved clinical outcomes, making it potentially preferable for most eligible patients once FDA approved.
Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.
Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.
Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).
The expert explored the complex prior authorization process for GLP-1 medications, discussing challenges in documentation and medical necessity.
In this roundtable, 3 pharmacy faculty members reflect on how shifting federal priorities and the defunding of research initiatives have impacted their work, communities, and careers—while highlighting the power of resilience, solidarity, and reimagined academic impact in advancing public health equity.
Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss the distinct adverse effect profiles of HER2- and HER3-targeted antibody-drug conjugates—particularly the risk and management of interstitial lung disease—and offer practical guidance based on clinical trial data and treatment protocols.
Panelists discuss how patient education should emphasize the importance of low-density lipoprotein cholesterol (LDL-C) management, the benefits and risks of therapy intensification, and how clinicians can navigate the expanding range of LDL-C–lowering agents by considering patient-specific factors such as cardiovascular risk, prior treatments, and cost-effectiveness.
Panelists discuss how clinical teams can identify and address nonadherence to statin and nonstatin therapies by leveraging electronic health record (EHR) systems for adherence monitoring and optimizing patient outcomes.
